Sustainable EDC Advantage P1’s real-time SDTM exports and direct EHR data acquisition via FHIR demonstrate a modern, standards-aligned platform that can reduce data handling and reconciliation effort for oncology and precision medicine trials, presenting a compelling case to CROs and biopharma firms seeking efficiency gains.

Rapid Implementation The platform claims 80% faster initial EDC builds and streamlined amendment/validation processes, offering a strong value proposition for sponsors running complex trial designs such as basket, master, umbrella, or platform programs.

Strategic Partnerships Existing collaboration with a top 5 CRO and multiple top pharma/biotech players indicates market validation and a track record of serving enterprise customers, suggesting upsell opportunities with large sponsors and expanded use within their trials.

Innovation Growth The launch of Clinical Pipe as a system-agnostic EHR-to-EDC connector highlights a growth vector into interoperability and ecosystem integration, enabling cross-system workflows that can attract new clients seeking seamless data flow across platforms.

Mid-market Focus With a lean team and revenue in the lower multi-millions range, Protocol First appears well positioned to target mid-sized biotech and specialty oncology programs looking for cost-effective, fast-to-implement EDC/CDMS solutions while expanding into larger accounts through partner channels.